Rakovina Therapeutics Inc. (RKV.V)

0.0850 0.0000 (0.00%) At close: 01:38PM EDT

Rakovina Therapeutics Inc.

999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada

https://www.rakovinatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A.	Executive Chairman	120k	N/A	1968
Dr. Mads Daugaard	President, CEO & Chief Scientific Officer	N/A	N/A	N/A
Mr. David Hyman CA, CBV	CFO & Corporate Secretary	120k	N/A	1973
Dr. John Langlands Ph.D.	Chief Operating Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.

Corporate Governance

Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.